|
Development Focus |
|
|
PROLOR Biotech is currently developing long-lasting versions for the following existing therapeutic proteins and peptides: |
 |
-
MOD-4023: hGH-CTP – $2.7 billion current market, no available long-lasting therapeutics
-
MOD-9023: IFN-ß-CTP – $4.7 billion current market, no available long-lasting therapeutics
-
MOD-5023: Factor VIIa-CTP – $1.2 billion current market, no available long-lasting therapeutics
-
MOD-7023: EPO-CTP - $10 billion current market, available long-lasting therapeutics
-
MOD-1001: GLP-1-CTP – $1.0 billion estimated potential market, no available long-lasting therapeutics
-
MOD-1002: OBES-CTP – $5.0 billion estimated potential market, no available long-lasting therapeutics |
